Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Obesity Policy Change Will Help Acomplia Launch, Sanofi Says

Executive Summary

Medicare's recent announcement about obesity coverage policies sends a positive signal for the upcoming launch of Sanofi-Synthelabo's Acomplia, the company said during a July 21 conference call

You may also be interested in...



Metabolic Syndrome Reimbursement Forecast: Outlook Remains Cloudy

In the near term, the best prospect for establishing a favorable reimbursement climate for metabolic syndrome may be to focus on treating comorbidities

Metabolic Syndrome Reimbursement Forecast: Outlook Remains Cloudy

In the near term, the best prospect for establishing a favorable reimbursement climate for metabolic syndrome may be to focus on treating comorbidities

Obesity Drugs May Be Covered Under Part D; CMS Invites Limits On Viagra

Drugs to treat "morbid obesity" may be covered by Medicare Part D plans despite the exclusion of "weight loss agents" from the program, CMS indicated in the final rules implementing the Medicare Rx benefit

Related Content

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel